保乳加放疗与乳房切除加重建术后患者报告生活质量的比较
该研究基于德克萨斯州癌症登记处2009-2014年诊断的0-II期乳腺癌患者,比较保乳加放疗(BCS+RT)与乳房切除加重建未放疗(Mast+Recon)的长期生活质量。共1215例受访者(应答率25.3%),中位调查间隔9年。调整分析显示Mast+Recon与较差的BREAST-Q心理社会健康(效应量-3.80,P=0.04)和性健康(效应量-5.41,P=0.02)相关,但PROMIS躯体功能更好(效应量0.54,P=0.03);仅性健康差异达临床显著性。
要点
- Mast+Recon术后长期性健康差于BCS+RT,差异达临床显著。
- ≥65岁患者从BCS+RT获益更大,<50岁患者从自体Mast+Recon获益更大。
- 化疗与多个生活质量领域受损相关。
核心结论
- Mast+Recon患者长期性健康差于BCS+RT,仅此差异达临床显著。
- 老年患者从BCS+RT获益更大,年轻患者从Mast+Recon获益更大。
研究设计与样本
- 基于德克萨斯州癌症登记处的队列研究,纳入2009-2014年诊断的0-II期乳腺癌患者。
- 按年龄和种族分层抽样,向4800例患者邮寄包含BREAST-Q和PROMIS模块的纸质调查。
- 共1215例受访(应答率25.3%),BCS+RT组631例,Mast+Recon组584例。
- 诊断至调查完成的中位间隔为9年,采用多变量线性回归模型分析。
主要发现
- 调整分析中,Mast+Recon与较差的BREAST-Q心理社会健康相关(效应量-3.80,P=0.04)。
- Mast+Recon与较差的BREAST-Q性健康相关(效应量-5.41,P=0.02),且达临床显著。
- Mast+Recon与更好的PROMIS躯体功能相关(效应量0.54,P=0.03)。
- BREAST-Q乳房满意度、躯体健康及PROMIS上肢功能两组差异无统计学意义(P>0.05)。
- ≥65岁接受BCS+RT及<50岁接受自体Mast+Recon的患者报告更高的生活质量评分;化疗与多个生活质量领域受损相关。
关键数值与推荐
- BREAST-Q最小临床重要差异为4分,PROMIS为2分。
临床怎么用
- 为早期乳腺癌女性提供偏好敏感决策信息时,应告知Mast+Recon可能带来长期性健康损害。
- 对老年患者可优先讨论BCS+RT,对年轻患者可讨论自体Mast+Recon的潜在生活质量优势。
- 化疗决策时需考虑其对多个生活质量领域的负面影响。
局限性
- 应答率25.3%,可能存在无应答偏倚。
- 为观察性研究,无法排除残余混杂。
- 仅纳入德克萨斯州患者,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare long-term quality of life (QOL) outcomes in breast cancer survivors who received breast-conserving surgery with radiotherapy (BCS+RT) with those who received a mastectomy and reconstructive surgery (Mast+Recon) without radiotherapy and identify other important factors. BACKGROUND: The long-term differences in patient-reported QOL outcomes following BCS+RT and Mast+Recon are not well understood. METHODS: We identified patients from the Texas Cancer Registry with stage 0-II breast cancer diagnosed in 2009-2014 after BCS+RT or Mast+Recon without radiotherapy. Sampling was stratified by age and race and ethnicity. A paper survey was sent to 4800 patients which included validated BREAST-Q and PROMIS modules. Multivariable linear regression models were implemented for each outcome. Minimal clinically important difference for BREAST-Q and PROMIS modules, respectively, was 4 points and 2 points. RESULTS: Of 1215 respondents (25.3% response rate), 631 received BCS+RT and 584 received Mast+Recon. The median interval from diagnosis to survey completion was 9 years. In adjusted analysis, Mast+Recon was associated with worse BREAST-Q psychosocial well-being (effect size: -3.80, P =0.04) and sexual well-being (effect size: -5.41, P =0.02), but better PROMIS physical function (effect size: 0.54, P =0.03) and similar BREAST-Q satisfaction with breasts, physical well-being, and PROMIS upper extremity function ( P >0.05) compared with BCS+RT. Only the difference in sexual well-being reached clinical significance. Older (≥65) patients receiving BCS+RT and younger (<50) patients receiving autologous Mast+Recon typically reported higher QOL scores. Receipt of chemotherapy was associated with detriments to multiple QOL domains. CONCLUSIONS: Patients who underwent Mast+Recon reported worse long-term sexual well-being compared with BCS+RT. Older patients derived a greater benefit from BCS+RT, while younger patients derived a greater benefit from Mast+Recon. These data inform preference-sensitive decision-making for women with early-stage breast cancer.
引用
- Diao K, Lei X, He W, et al. Patient-reported Quality of Life After Breast-conserving Surgery With Radiotherapy Versus Mastectomy and Reconstruction. Ann Surg. 2023. PMID: 37232937. doi:10.1097/SLA.0000000000005920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。